Short answer · Medically reviewed summary · Last updated: 2026-05-08
The ICD-10-CM code for Insulinoma of the pancreas is D13.7 (benign neoplasm of the pancreas), while the ICD-9-CM code historically used is 211.7. These codes are essential for medical documentation, insurance billing, and tracking clinical data for patients living with this rare neuroendocrine tumor. What is the clinical significance of Insulinoma coding? Insulinoma is a rare, typically benign tumor of the pancreas that secretes excessive insulin, leading to recurrent hypoglycemia.
ICD10 code of Insulinoma and ICD9 code
ICD-10 and ICD-9 codes for Insulinoma, with classification details for clinicians, coders and patients.
The ICD-10-CM code for Insulinoma of the pancreas is D13.7 (benign neoplasm of the pancreas), while the ICD-9-CM code historically used is 211.7. These codes are essential for medical documentation, insurance billing, and tracking clinical data for patients living with this rare neuroendocrine tumor.
What is the clinical significance of Insulinoma coding?
Insulinoma is a rare, typically benign tumor of the pancreas that secretes excessive insulin, leading to recurrent hypoglycemia. Because Insulinoma requires specialized surgical intervention and endocrinology management, accurate coding—such as D13.7 in the ICD-10 system—is vital for ensuring patients receive appropriate insurance coverage and coordinated care. Currently, 15 members in the DiseaseMaps community have shared their experiences with Insulinoma, highlighting the importance of standardized medical classification for rare disease navigation.
How is a diagnosis of Insulinoma confirmed?
Diagnosis typically involves a 72-hour supervised fast to provoke hyperinsulinemic hypoglycemia. Clinicians use specific biochemical criteria to confirm the presence of Insulinoma, including elevated serum insulin, C-peptide, and proinsulin levels during a hypoglycemic event. Once biochemical suspicion is high, imaging is used to localize the tumor.
Common diagnostic and clinical features of Insulinoma
When evaluating Insulinoma, medical teams look for a specific constellation of findings known as Whipple's Triad. Key clinical aspects include:
- Whipple’s Triad: Symptoms of hypoglycemia, low plasma glucose concentration, and relief of symptoms after glucose administration.
- Prevalence: It is estimated to occur in approximately 1 to 4 individuals per million people per year.
- Genetic Association: While most cases are sporadic, approximately 5-10% of Insulinoma cases are associated with Multiple Endocrine Neoplasia type 1 (MEN1).
- Localization: Over 90% of these tumors are benign and solitary, requiring precise localization via endoscopic ultrasound or selective arterial calcium stimulation.
Next steps
- Consult an endocrinologist experienced in neuroendocrine tumors to discuss diagnostic testing.
- Request a referral to a high-volume surgical center if Insulinoma is confirmed.
- Connect with the 15 Insulinoma patients on DiseaseMaps.org to share insights and support.
- Maintain a detailed symptom diary to assist your medical team in identifying patterns of hypoglycemia.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or qualified health provider.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Insulinoma.
- Orphanet: Insulinoma (ORPHA:468).
- OMIM (Online Mendelian Inheritance in Man): #606333 (Multiple Endocrine Neoplasia, Type I).
- World Health Organization (WHO) Classification of Tumours: Endocrine Organs.
